Project Grant R50CA283807
Award Date
9/12/24
Completion Date
8/31/29
Dollars Obligated
$112K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $552,763 to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, to conduct research on KAT6A as a novel druggable target for cancer treatment. The research aims to assess the therapeutic potential of newly developed KAT6 inhibitors (KAT6Is) as monotherapy and in combination with targeted therapy drugs in preclinical...
This $530,697 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Pennsylvania to investigate the use of protein arginine methyltransferase (PRMT) inhibitors for treating high-grade serous ovarian cancer and triple-negative breast cancer. The key objectives are to: 1) characterize the molecular mechanisms of PRMT inhibitor mono- and combination therapies, 2) evaluate the therapeutic potential of PRMT inhibitors in...
This $1,178,136 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania. The research project, titled "EXPLOITING ABSENCE OF TP53 MUTATIONS IN EPITHELIAL OVARIAN CANCER WITH NEXT-GENERATION P53-STABILIZING AGENTS," aims to advance disease prevention, diagnosis, treatment,...
This Project Grant award, valued at $597,766.00, is funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The University of Pennsylvania will develop novel methods to image two PET tracers with different molecular targets back-to-back in a single imaging session using a long-axial field-of-view PET scanner, the PennPET Explorer. The key objectives are: Develop protocols to image fluoroglutamine, a research radiotracer of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) totaling $227,906 will support the development of a novel technology for spatially resolved multi-omics sequencing of formalin-fixed paraffin-embedded (FFPE) tissue samples at the cellular level. The key products and services to be delivered under this award include: Developing spatial epigenome sequencing capabilities to measure gene expression and epigenetic characteristics directly in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides USD 1,373,308 in funding to the University of Pittsburgh from January 1, 2025 to December 31, 2029. The project aims to investigate a metabolic mechanism involving acetylcarnitine that may contribute to chemoresistance in high-grade serous ovarian carcinoma (HGSOC). The research will: 1) quantitatively and mechanistically map the acetylcarnitine-dependent histone acetylation axis and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to develop a protein therapeutic that can limit the transformation of a patient's own anti-tumor autoantibodies into bispecific T cell-redirecting antibodies, in order to enhance the immune-mediated clearance of tumor cells. The primary objectives are to: 1) Optimize the engineered protein therapeutic to target the tumor microenvironment, and 2) Determine the distribution and...
This $132,015 Project Grant award was provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to The Ohio State University. The funding will support efforts to improve enrollment in clinical trials for gynecologic cancers, especially among underrepresented populations. Key activities include: Developing a comprehensive system at The Ohio State University Comprehensive Cancer Center to streamline molecular matching and identification of patients for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $205,700 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The research will evaluate how intrinsic tumor features contribute to the development of resistance, and test a novel combination approach of DNA repair inhibition and targeted therapy to prevent...